Challenges and Opportunities for Developing Countries Regarding Life-sciences Innovation

Stephen Ezell
VP, Global Innovation Policy
ITIF

Global Trade and Innovation Policy Alliance Annual Summit

Mexico City, Mexico
June 13, 2019
Innovate4Health Initiative
IP boosts innovation in Malaysian cervical cancer screening

Innovate4Health: Investigadores chilenos desarrollan un tratamiento...

Innovate4Health: Chilean Researchers Develop Stem Cell Therapy Treatments...

Nueva empresa colombiana de biotecnología cura heridas

Geneva Network - Apr 26 - 5 min read

ITIF - Apr 26 - 5 min read

Geneva Network - Mar 14 - 6 min read

ITIF - Apr 26 - 5 min read

ITIF - Apr 26 - 5 min read

ITIF - Mar 14 - 6 min read
Innovate4Health: IP-driven Innovation In Healthcare Is Happening Everywhere
Lessons Learned From the I4H Case Studies

- Developing countries have unique challenges, but global health challenges are increasingly commonly shared.
  - 70% of fatalities in developing world from non-communicable diseases.

- However, access challenges remain significant.
  - More than two billion individuals lack adequate access to essential medical products/supplies.

- Innovative medicines are part of the solution, not the problem.
# Mexico’s Robust Life-Sciences Sector

## Mexican pharmaceutical industry

Mexico has the 2nd largest biopharmaceutical market in Latin America and the 11th largest in the world.

<table>
<thead>
<tr>
<th>Metric</th>
<th>Value</th>
<th>Note</th>
</tr>
</thead>
<tbody>
<tr>
<td>Proportion of GDP</td>
<td>1.2%</td>
<td>Growth of 0.7% from 2007</td>
</tr>
<tr>
<td>Proportion of Manufacturing GDP</td>
<td>6.8%</td>
<td>Significant manufacturing sector in Mexico</td>
</tr>
<tr>
<td>Direct Jobs</td>
<td>86,277</td>
<td>37% linked to manufacturing</td>
</tr>
<tr>
<td>Indirect Jobs</td>
<td>313,605</td>
<td>Includes jobs in other companies from which the pharmaceutical industry buys goods or services</td>
</tr>
<tr>
<td>Sector growth</td>
<td>4.3%</td>
<td>Between 2007 and 2013</td>
</tr>
<tr>
<td>Economic units</td>
<td>718</td>
<td>Companies located mainly in Mexico City, Jalisco, Estado de México and Puebla.</td>
</tr>
<tr>
<td>Multinational biopharmaceutical industry</td>
<td>20 of 25</td>
<td>Top multinational biopharmaceutical companies operate in Mexico</td>
</tr>
<tr>
<td>Investment in R&amp;D</td>
<td>US$500m by 2025</td>
<td>Increase of US$160m from 2015</td>
</tr>
<tr>
<td>Biotechnology drugs</td>
<td>65% by 2030</td>
<td>Proportion of patent applications for new medicines</td>
</tr>
</tbody>
</table>

Sources: Mexican Health Review 2015, Marketline, INEGI, COFEPRIS, Denue and CANIFARMA. Courtesy Fundacion IDEA.
Life-Sciences Innovation Strengths in Mexico

- A cost-competitive environment for life-sciences innovation.

<table>
<thead>
<tr>
<th>Competitive costs (% of savings)</th>
</tr>
</thead>
<tbody>
<tr>
<td>-35.9% R&amp;D in biotechnology</td>
</tr>
<tr>
<td>-31.5% Clinical trials</td>
</tr>
<tr>
<td>-39.3% Product testing</td>
</tr>
<tr>
<td>-14.4% Pharmaceutical manufacturing</td>
</tr>
</tbody>
</table>

- Increasingly skilled human capital base for biomedical research.

- Diverse ecology (and society) a platform for biomedical innovation.

Source: The Geneva Network, ProMexico, ITIF
Life-Sciences Innovation Opportunities for Mexico

- Recognize that biopharmaceutical value creation comes from R&D and clinical trials, not from the manufacturing.
- Enhance R&D collaboration between biopharmaceutical industry, research institutions, and universities.
- Appropriately value and speed patient access to innovative medicines.
- Continue to improve the intellectual property environment.
- Set a goal of becoming a “G20” life-sciences innovator.
Muchas Gracias!

Stephen Ezell  |  sezell@itif.org  |  202.465.2984